Abstract The purpose of this study was to systematically review the utility of single-photon emission tomographycomputed tomography (SPET-CT) fusion imaging in the investigation of thyroid cancer. We performed a systematic search of the world literature on radionuclide SPET-CT imaging of thyroid cancer using the medical databases Medline (OVID) and PubMed. The following search terms were used to identify relevant studies: (a) thyroid, combined with (b) SPECT/CT or SPECT-CT or SPET/CT or SPET-CT. The electronic searches returned citations for 1,189 potentially eligible articles and 98 abstracts were reviewed for relevance by two co-authors. Thirty-one peerreviewed full articles reporting the utility, value and diagnostic performance of radioiodine SPET-CT for the imaging of well-differentiated thyroid cancer were selected. The quality of these studies was assessed using the quality assessment of diagnostic accuracy studies-2 tool.
Introduction
The avidity of thyroid tissue for radioiodine and the various applications of radioiodine in the evaluation of thyroid disease have served as the prototype for numerous subsequent functional imaging procedures in nuclear medicine. Since the earliest attempts to depict the distribution of radioiodine with rectilinear scanners, thyroid imaging, like other nuclear medicine examinations, has undergone a significant evolution, progressing from planar scans (first presented on paper) to three-dimensional single-photon emission tomography (SPET) and, most recently, to simultaneously acquired SPET and computed tomography (CT), i.e., SPET-CT, with images viewed on high-resolution digital computers. Although advancing technology has markedly improved the efficacy of nuclear imaging, the fundamental information provided by the patterns of radioiodine uptake has not changed from the early beginnings of this approach. The accumulation of radioiodine by the thyroid sodium-iodide symporter (NIS) is the molecular basis for its clinical utility [1] [2] [3] and today, seven decades since its introduction, radioiodine continues to be a cornerstone in the management and treatment of well-differentiated thyroid cancer (WDTC) [4] . The incidence of WDTC is increasing both in adults and in the pediatric population largely because of earlier detection and diagnosis at a smaller tumor size, although unidentified environmental factors probably play a role too [5] . Because microcarcinoma (size B1 cm) accounts for an increasing proportion of newly diagnosed thyroid cancers [6, 7] , the role of radioiodine in the management of WDTC is under scrutiny in low-risk patients, who do not show extrathyroidal extension or high-risk histopathology features [8] . WDTC has an excellent prognosis, with a ten-year survival rate of 85 % in follicular thyroid cancer and greater than 90 % in papillary thyroid cancer. Factors related to mortality from WDTC include age, gender, tumor characteristics (type, grade, size, and invasiveness) and clinical stage at diagnosis [9] [10] [11] . There is currently a movement away from the staging of thyroid cancer using classification systems that provide information on mortality, e.g., American Joint Committee on Cancer, Tumor Node Metastasis (AJCC TNM), in favor of a risk stratification design that predicts recurrence risk and allows more informative management decisions [4, 12] . Although the literature supports the use of I-131 in the treatment of local and distant metastases of WDTC [9, 10] , there is no compelling evidence that it decreases recurrence or increases survival in low-risk, stage I patients [9-11, 13, 14] . Concurrently, exploration of lower dosages of I-131 for thyroid remnant ablation has provided convincing evidence for efficacy of this approach from doses as low as 1.1 GBq (30 mCi) of I-131. Furthermore, recombinant human thyrotropin (rhTSH: Thyrogen Ò ) stimulation has been accepted as an alternative to thyroid hormone withdrawal for diagnostic radioiodine imaging and for performing thyroid remnant ablation [15, 16] . However, the use of this approach, compared with endogenous hypothyroidism, for the treatment of iodine-avid metastases remains to be validated. Around one-third of patients with WDTC will have recurrences in their lifetime, most of which will be noniodine-avid; for these patients, multikinase inhibitor treatment offers promise for disease stabilization.
These innovations in the management of WDTC have been accompanied by technological advances in nuclear medicine image acquisition. Planar gamma camera images have been augmented with three-dimensional SPET allowing improved localization of metastatic disease and its differentiation from physiological anatomical variants. More recently, a further significant increase in interpretative accuracy and localization has been achieved with the introduction of simultaneously acquired radioiodine SPET-CT.
Our aim was to systematically review the utility of hybrid SPET-CT imaging for the investigation of thyroid cancer, focusing in particular on radioiodine imaging in WDTC as this makes up the bulk of the current literature.
Materials and methods

Literature search to identify studies
On March 1st, 2014, we performed a literature search for articles reporting the diagnostic utility of SPET-CT for the imaging of thyroid cancer focusing in particular on its use in WDTC. The bibliographic databases searched were Medline (OVID) and PubMed. The initial search strategy proved to be very effective. It was performed using the search words: (a) thyroid, and (b) SPECT/CT or SPECT-CT or SPET/CT or SPET-CT or hybrid or fusion, combined in the search engine in Medline (OVID) from 1946 to February, 2014. The list of citations obtained was then restricted to the period from 2003 onwards as this is the year of the first report of SPET-CT applied in a cohort with WDTC. The Medline search was augmented with a population index comparator outcome (PICO) search strategy which returned only one additional article for consideration. Individual searches were performed on each PICO parameter as relevant to the review topic, then the returned citations/hits were variously combined using the search engine functionality (e.g., PI, PIC, PICO) to include as many relevant articles as possible. Finally, a PubMed search was performed using the term radioiodine SPECT-CT which found an additional 18 articles for consideration. The list of articles was extended by cross-checking of all reference lists of retrieved articles. This revealed three extra articles for consideration. Details of the search strategy are summarized in Fig. 1 . A complete list of search terms and strategy is provided in ESM Appendix 1.
Selection criteria
Two reviewers (K.K.W. and D.J.W.) independently performed the searches. Inclusion criteria were peer-reviewed articles describing original research pertaining to radioiodine SPET-CT evaluation of WDTC and other indications associated with thyroid cancer. Exclusion criteria included non-English language or literature and studies not using the SPET-CT technique.
Data extraction
Using the quality assessment of diagnostic accuracy studies-2 (QUADAS-2) tool relevant retrieved articles were reviewed for quality, applicability and risk of bias [17] . Due to significant heterogeneity arising from variability in patient cohorts, study design, imaging protocols and techniques, result reporting, and gold standard for follow-up, a systematic review analysis was conducted rather than using meta-analytical methods.
Study characteristics, test parameters and endpoints
The following parameters were extracted: (1) first author and year of publication; (2) study design; (3) description of patients; (4) radioiodine isotope and dose; (5) indication for SPET-CT; (6) type of hybrid SPET-CT camera and imaging parameters of the CT component; voltage and current; and (7) main findings. This present review summarizes the content of 31 original articles reporting the utility and diagnostic performance of SPET-CT for the investigation of WDTC. The systematic review was performed according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines [18] .
Results
Study selection and characteristics analysis
The electronic searches returned citations for 1,189 potentially eligible articles and two reviewers viewed the titles independently to determine their relevance. There were 98 potentially relevant articles including reviews and pictorial essays (n = 23), case reports, editorials, and letters (n = 31), and miscellaneous articles reporting investigative uses of SPET-CT for thyroid cancer, including use in medullary thyroid cancer (n = 14). After review of the abstracts of these articles, a total of 30 articles were retrieved in full pertaining to SPET-CT imaging of WDTC. After cross-checking of all reference lists, one additional article of relevance was retrieved, resulting in a total of 31 original articles. Quality assessment of diagnostic accuracy studies
Using the QUADAS-2 tool, the studies were evaluated in four domains for risk of bias and applicability (see Table 1 ). It was noted that a few of the 31 studies had cohorts that overlapped with previously published reports. However, as the study designs focused on different questions, this was unlikely to affect the conclusions drawn. For example, some patients included in studies investigating incremental diagnostic value were subsequently included in studies investigating impact on cancer staging. Two studies were at high risk for selection bias due to the use of SPET-CT solely in intermediate and high-risk patients, with low-risk patients excluded from receiving the index test. Other studies had a potential bias based on the selective use of the index test; however, the risk was again considered low. Most studies lacked histopathological findings, instead relying on clinical follow-up and correlative imaging.
Study characteristics and protocols for SPET-CT
The identified I-131 and I-123 SPET-CT studies concerned patients prepared with either endogenous hypothyroidism or exogenous recombinant human TSH stimulation, and they used diagnostic imaging doses ranging from 37 to 430 MBq (1-11 mCi) [19] [20] [21] [22] [23] [24] and post-therapy imaging doses ranging from 1.1 to 9.7? GBq (30-260? mCi) [20, [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] . Radioiodine SPET-CT was used for surveillance for thyroid cancer recurrence, before I-131 therapy [19, 20, 27, 41, 42] , in the post-surgical setting for radioiodine ablation of normal thyroid remnants, [21, 22, 24] , or in post-therapy imaging [25-30, 32, 33, 36, 37, 39, 40, 43-45] .
The study characteristics and summary findings are presented in Tables 2 and 3 .
Discussion
Radioiodine SPET-CT imaging of well-differentiated thyroid cancer Planar and SPET gamma camera imaging with I-131 suffers from inherent poor spatial resolution and septal penetration artifacts that arise from the high energy 364 keV gamma emissions [46] [47] [48] [49] . Despite its high spatial resolution and fine anatomical detail, CT has been used sparingly in thyroid cancer because of the effects of iodinated contrast on thyroid function; indeed, it results in decreased subsequent radioiodine uptake and, therefore, impairs I-131 treatment intent. In addition, metastases may occur in lymph nodes that are anatomically normal in size and morphology, resulting in false-negative CT evaluations. Many of the drawbacks with thyroid cancer imaging using separate radioiodine scintigraphy and CT have been mitigated by hybrid SPET-CT scanners, where simultaneous SPET and CT (usually non-contrast-enhanced) information can be directly combined [19-23, 25-45, 50-53] .
I-131 SPET-CT was first reported by Even-Sapir and colleagues in four cases of thyroid cancer included in a larger group of endocrine neoplasms [54] . Other investigators later found that SPET-CT improved diagnostic evaluation compared to SPET alone in 15/17 (88 %) thyroid cancer patients [38] . Tharp and colleagues reported increased diagnostic value of SPET-CT versus planar imaging in 41/71 (57 %) patients, noting that the anatomical information from low-resolution (non-diagnostic) CT better differentiated equivocal neck lesions encountered on planar images [20] . Furthermore, in 36 patients with extrathyroidal disease, SPET-CT distinguished I-131 foci of uptake as benign in nine patients, and confirmed bone metastases in 12 patients and lung metastases in five patients, changing the subsequent management plans. These early observations of the potential utility of radioiodine SPET-CT have since been confirmed in larger published studies.
SPET-CT diagnostic interpretation
SPET-CT allows precise localization and easier differentiation of benign radioiodine uptake in remnant thyroid tissues from malignant radioiodine accumulation in metastatic cervical lymph nodes or distant metastases (Fig. 2) . It is widely accepted that I-131 SPET-CT reduces the equivocal findings frequently encountered on planar imaging. Maruoka and colleagues, in 147 patients, compared post-therapy I-131 SPET-CT scans to whole-body planar radioiodine scans and reported that SPET-CT clarified 25 equivocal interpretations on planar imaging as either metastatic regional lymph nodes or thyroid remnant tissues. SPET-CT further characterized 21 out of 52 (40 %) foci of I-131 uptake, differentiating metastases from benign, physiological mimics of disease [28] . In a similar fashion, diagnostic I-131 SPET-CT performed before thyroid remnant ablation accurately characterized central neck and distant distributions of I-131 activity, correctly classifying equivocal planar imaging findings as benign or malignant [22, 23] . The incremental value of SPET-CT over planar imaging was reported in 53 out of 130 (41 %) foci, with confident identification of thyroglossal duct and thyroid bed remnants [22, 23] . Others have confirmed that indeterminate neck lesions on planar scans, when restudied with SPET-CT, can be re-classified as thyroid remnants, lymph node metastases (Fig. 3) , radioiodine contaminated oropharyngeal secretions, or other physiological variants (86, 89) (Fig. 4) .
I-131 planar imaging has a reported sensitivity of 45 to 75 % and specificity of 90 to 100 %, depending on the administered dosage [19, 20, 46] . Barwick and colleagues reported that I-123 SPET-CT imaging for thyroid cancer recurrence had higher sensitivity (50 %), specificity (100 %) and accuracy (87 %) values compared to SPET alone (sensitivity 45 %, specificity 89 % and accuracy 78 %) and planar imaging (sensitivity 41 %, specificity 68 % and accuracy 61 %). They concluded that the main value of I-123 SPET-CT was that it offered increased imaging specificity [41] . Another benefit of the CT component reported by Menges and colleagues is its ability to identify non-iodine-avid tumor, resulting in sensitivity increasing from 62 to 74 %, with unchanged high specificity of 98 % (Fig. 5) [29] . Confirming this, other authors found that I-131 SPET-CT depicted additional non-iodineavid disease in 32 out of 148 (21.6 %) patients with an intermediate-to-high risk of thyroid cancer recurrence [40] . The detection of non-iodine-avid disease, shown by loss of NIS expression (seen in 20-30 % of patients with WDTC), signifies that radioiodine treatments will no longer be effective. Current data in the literature show that SPET-CT reduces the number of equivocal findings, improves imaging specificity, and can detect metastatic disease without radioiodine concentration in some patients.
Metastatic thyroid cancer and SPET-CT I-131 SPET-CT is useful for whole-body screening for distant metastatic disease [19, 21, 22, 27-29, 37, 39, 41] .
Clin Transl Imaging (2014) 2:459-475 463 I-131 SPET-CT can be used to localize early skeletal metastases (prior to radiographic abnormality) as well as metastases in the lungs and mediastinal lymph nodes (Fig. 6 ). Qiu and colleagues reported that I-131 SPET-CT exhibited significantly higher sensitivity than 99m Tc-methylene diphosphonate ( 99m Tc-MDP) bone scans in depicting thyroid cancer metastases to bone [44] . Song and colleagues described distant metastatic disease depicted on I-131 SPET-CT, including some unusual sites [34, 35] . Additional reports have confirmed the value of I-131 SPET-CT in localizing unanticipated metastases of thyroid cancer to the trachea, muscle, liver and kidneys [53, [55] [56] [57] [58] [59] [60] [61] [62] [63] . Furthermore, I-131 SPET-CT accurately identifies cervical nodal metastases that may be present in anatomically normal lymph nodes and not readily identified on post-thyroidectomy neck ultrasound [52] . SPET-CT can identify metastatic disease in the neck and at distant sites, improving image interpretation and reducing the need for correlative diagnostic CT or MRI.
Benign remnant thyroid tissues and physiological variants evaluated with SPET-CT Numerous physiological variants and potential disease mimics are recognized and well described on radioiodine scintigraphy [64] [65] [66] . In addition to thyroid cells, NIS activity can be found in salivary glands, gastric mucosa, and lactating and non-lactating breasts [67] . Radioiodine uptake has also been identified in lacrimal glands, choroid plexus, the ciliary body of the eye, skin, placenta, and thymus [1, [67] [68] [69] [70] [71] . It is estimated that at least 22 % of radioiodine scans will have cryptic findings including benign mimics of disease [42] . Although the majority of these normal variants are correctly identified on planar imaging, SPET-CT helps to resolve diagnostic uncertainty, increasing interpretation confidence and accuracy [72, 73] .
Multiple case reports confirm this utility of SPET-CT in distinguishing an increasing list of benign mimics of disease that include obstructed nasolacrimal duct(s), lingual thyroid(s), thymus, struma ovarii, ovarian teratomas, menstruating uterus and renal cysts [53, [55] [56] [57] [58] [59] [60] [61] [62] [63] [74] [75] [76] [77] [78] (Fig. 7) . Two papers independently reported the utility of SPET-CT for investigation of a physiological mechanism of radioiodine uptake not previously described in the literature. Savas and colleagues reviewed 216 SPET-CT scans and found that oral radioiodine uptake was present on 123 (57 %) [79] and postulated an affinity of radioiodine for metals via a semi-permanent chemical reaction. Others studied 58 post-therapy patients with SPET-CT and confirmed that 91 % showed focal radioiodine localizing to dental restorations [80] .
Investigators from Australia retrospectively evaluated post-therapy SPET-CT in 83 consecutive patients paying particular attention to the presence of remnant thyroid tissue located along the thyroglossal tract [81] , i.e., thyroid tissue remaining along the embryological path of thyroid Fig. 4 Benign salivary gland activity found in a 78-year-old woman post-total thyroidectomy for papillary thyroid cancer. Diagnostic 4 mCi I-131 planar image (a) demonstrates focal uptake in the right side of the neck suspicious for lymph node metastasis (arrow). Axial CT (b) and SPET-CT (C) localize the neck activity to the salivary glands with more intense radioiodine uptake seen in the right gland which is larger than the left gland (arrow). This asymmetric salivary gland physiological uptake may occur following radioiodine administration (color figure online) However, adjacent to this, there is a lowattenuation necrotic pretracheal mass that does not accumulate radioiodine activity compatibly with non-iodine-avid disease (arrowheads). There was no iodine uptake demonstrated within metastatic disease in the mediastinum, liver, bone and abdomen detected with FDG PET/CT imaging. After imaging, the patient was restaged as T4a N1b M1, stage 4C, classified as high ATA risk. Recommendation was for high-dose I-131 treatment and referral for external beam radiation therapy (color figure online) descent from the foramen cecum (near the tongue) to the thyroid bed. This tissue is not usually removed with total thyroidectomy and can create diagnostic uncertainty on post-surgical TSH-stimulated planar radioiodine scans [22, 23] . This thyroglossal tract thyroid tissue was reported to be present in 39/83 (47 %) patients and could be accurately characterized on SPET-CT. The investigators observed that some of the total dosage of radioiodine was administered with the aim of ablating these otherwise benign postsurgical findings in these patients. SPET-CT can confidently confirm that uptake in the neck and elsewhere in the body is benign in nature, preventing misinterpretation of findings as metastatic disease.
Comparison with other imaging modalities in thyroid cancer
Qiu and colleagues compared the diagnostic performance of 99m Tc-MDP bone scans, I-131 SPET-CT and 18 F-FDG PET in patients with suspected bone metastases. I-131 SPET-CT had a sensitivity of 92 % and a specificity of 98 %, which were values similar to those recorded for 18 F-FDG PET (sensitivity of 85 %, specificity of 88 %). Both these modalities were superior to 99m Tc-MDP bone scans, which had a sensitivity of 73 % and a specificity of 74 % [44] . In a retrospective study of 140 patients suspected of having metastatic disease based on imaging and serum thyroglobulin, Oh and colleagues reported a sensitivity of 65 % and a specificity of 95 % for I-131 SPET-CT, similar to the values for 18 F-FDG PET and higher than those of whole-body I-131 planar scans [43] . In this investigation, I-131 SPET-CT outperformed 18 F-FDG PET after a single I-131 treatment, while the sensitivity of 18 F-FDG PET was better than that of I-131 SPET-CT in patients after multiple radioiodine treatments [43] . Imaging with I-131 SPET-CT and 18 F-FDG PET provides complementary diagnostic information that assists in the management of patients with WDTC and should be ordered on the basis of the specific clinical situation.
Preliminary data suggest that the sensitivity of I-124 PET/CT is higher than that of post-therapy I-131 SPET-CT for the detection of radioiodine lesions (remnants or metastases). de Pont and colleagues reported a study that compared pretreatment I-124 PET/CT with post-therapy I-131 SPET-CT in 20 patients. I-124 PET/CT performed best, identifying 92 % of total foci, whereas radioiodine SPET-CT identified 81 % and planar imaging only 63 %. Staging and management were changed in 25 % of patients, three of whom were detected only with PET/CT [82] . Impact of SPET-CT on thyroid cancer staging, management and prognosis Accurate staging and risk stratification are critical considerations in the management of thyroid cancer. Post-therapy I-131 SPET-CT studies [20, 25, 26, 30, 33, 37, 40] and follow-up diagnostic scans after thyroid remnant ablation [19, 41] have demonstrated improved characterization of nodal (N) and distant metastases (M) status on TNM staging schema. At the first radioablation therapy, posttherapy SPET-CT was found to restage the cervical N status in 20/57 (35 %) patients [33] . Similarly, Kohlfuerst and colleagues noted that SPET-CT changed the N score in 12/33 (36.4 %) and M score in 4/19 (21.4 %) of patients with inconclusive post-therapy planar scans, resulting in changes in management in 10/41 (24.4 %) patients [27] . It is obvious that identification of the presence of locoregional and/or distant metastatic disease prior to thyroid remnant ablation alters subsequent patient management. Pre-ablation SPET-CT altered TNM staging in 10/48 (21 %) patients, resulting in reconsideration of the proposed I-131 therapeutic dose in 28/48 (58 %), with lower administered radioiodine, 1.1 GBq (30 mCi), in low-risk patients with the goal of performing remnant ablation only, and higher doses 3.7-7.7? GBq (100-200? mCi) when the intention was to treat persistent iodine-avid thyroid cancer [21] . The effect of I-131 SPET-CT on N and M scores and TNM stage was assessed in 320 patients evaluated at the time of planned thyroid remnant ablation. In 138 patients\45 years old unanticipated distant metastases were identified in five (4 %) and nodal metastases in 61 patients (44 %), while in 182 patients older than 45 years distant metastases were found in 18 (10 %) and nodal metastases in 51 patients (28 %). With the additional information obtained from I-131 SPET-CT scanning, TNM staging was changed in 4 % of patients aged under 45 years, and in 25 % of those over the age of 45 [24] .
In a cohort of 290 patients at intermediate risk, as established by the American Thyroid Association (ATA) thyroid cancer guidelines risk assessment [4] , who had undergone radioiodine treatment, retrospectively selected on the basis of negative or low thyroglobulin, SPET-CT was found to disclose unsuspected disease in the neck and the lungs even in patients with undetectable post-surgical thyroglobulin levels [83] .
SPET-CT has been used to study the incidence of nodal metastases in T1 tumors. In a study of 151 patients using a combination of pN1 (nodal disease found on the pathology specimen from surgical neck dissection) and sN1 (nodal disease detected on SPET-CT imaging), lymph node metastases were identified in 26 % of T1 stage (B2.0 cm) tumors and in 22 % of small primary tumors (B1.0 cm), with obvious implications for risk stratification and management [30] . Another study using diagnostic SPET-CT found that T1a tumors were associated with nodal metastases in 28/49 (57 %); unsuspected distant metastases were found in 2/49 cases (4 %) [24] . In a study of thyroid microcarcinoma, SPET-CT on post-therapy imaging was used to confirm a significant proportion (26/30 patients) as having regional nodal metastatic disease: the proportion of patients with N1 disease was 30/85 (35 %) [84] .
The results of radioiodine SPET-CT imaging lead to changes in clinical management that include subsequent use of therapeutic radioiodine, modification of the extent of surgery, the use of external beam radiation therapy, and the inclusion of alternative imaging procedures (e.g., 18 F-FDG PET). SPET-CT with either I-123 or I-131 accurately Fig. 7 Benign mimic of distant metastases found in a 48-year-old woman post-total thyroidectomy for papillary thyroid cancer. Posttherapy scan obtained several days after 100 mCi I-131. Anterior planar image (a) demonstrates focal uptake in the right side of the pelvis that was not present on the diagnostic scan (arrow). Axial SPECT (b) confirms the presence of focal activity in the right pelvis (arrow). Axial unenhanced CT (c) and fused SPET-CT (d) localize the activity to a benign cystic teratoma (dermoid) of the right ovary (arrows). SPECT-CT accurately characterized this lesion as benign mimic of malignancy and avoided the misdiagnosis of distant metastases (color figure online) localized all neck foci including benign etiologies in 13 children with WDTC, depicted additional foci of I-131 accumulation not identified on planar imaging in two, and changed the clinical decision (ruling out I-131 therapy) in two others [51] . It is, in fact, important to avoid unnecessary radiation exposure where residual and/or metastatic disease has been excluded [85, 86] . SPET-CT can characterize focal I-131 central neck uptake as benign thyroid remnants, thereby reducing the dose requirements or even eliminating the need for radioiodine therapy in some patients [87] .
Important prognostic information regarding the success of radioiodine treatment is provided by I-131 SPET-CT imaging. In a short-term follow-up study, Schmidt and colleagues [32] reported that an involved neck nodal volume of \0.9 ml, estimated using SPET-CT, was highly likely to respond to I-131 therapy without surgical intervention. Other authors found that the presence (or absence) of I-131 uptake on post-therapy SPET-CT can be used to better predict short-term outcome and failure of I-131 therapy compared with planar imaging alone [25] . Ciappuccini and colleagues performed post-therapy SPET-CT imaging in 170 patients to identify prognostic factors predicting treatment failure at 2 years. In this study, TNM staging, macroscopic cervical lymph node disease, and positivity of planar and SPET-CT imaging were identified as significant predictive factors, with SPET-CT as the only independent prognostic indicator [26] . Radioiodine SPET-CT assists risk stratification of WDTC, can predict failure of radioiodine treatments, and gives insight into the prognosis of patients with WDTC.
SPET-CT derived tumor dosimetry
Radioiodine SPET-CT imaging can be used to identify patients with unsuspected metastatic disease and thus to define targets for I-131 therapy, rather than relying on blind empiric treatments. The information obtained from imaging can be used to determine tumor dosimetry, particularly when high-dose I-131 therapy is being considered [21, 88] . It is well established that absorbed doses of [7,800 cGy are necessary to ablate residual carcinomas [89, 90] . While the general goal of initial I-131 therapy is to ablate as much tumor as possible, most therapies are planned with standard doses of radioiodine, limiting the role of tumor dosimetry, the best predictor of therapeutic success, to more complicated patients. Until recently, calculation of absorbed radiation dose in affected lymph nodes was problematic in the absence of accurate measurement of tumor volume. SPET-CT can be used to better define the volume of metastatic disease and thereby provide more accurate tumor dosimetry. Its use to deliver tailored doses of radiation to the tumor has been reported in a patient with a large metastasis to the skull [91] and in a case of diffuse bone metastases [92] .
Limitations of SPET-CT
The spatial resolution of SPET-CT is limited in small lesions by partial volume averaging that excludes delineation of small lymph node metastases. Accurate tumor staging, therefore, requires knowledge of the histopathological status of extrathyroidal extension and the presence or absence of disease at surgical margins for T staging and the status of central lymph nodes for N staging. Misregistration of radioiodine and CT datasets, either as a result of patient motion or normal physiology (e.g., respiratory motion) may complicate image fusion and scan interpretation.
SPET-CT for imaging medullary thyroid cancer
Medullary thyroid cancers (MTCs) are derived from parafollicular (C cells) of neural crest origin, and they account for 3-12 % of all thyroid cancers. MTC is an indolent disease and after surgery up to 40 % of patients will have residual or recurrent disease, as indicated by elevated serum calcitonin or carcinoembryonic antigen tumor biomarkers [93] In-octreotide (50-75 %) [94] and recently 99m Tc-EDDA/HYNIC-TOC (80 %) [95] . 111 In-octreotide SPET-CT was able to depict a paratracheal MTC recurrence [96] , while another report described a MEN2B patient with 99m Tc-(V)DMSA SPET-CT imaging of bone metastases [97] . To our knowledge, due to the rarity of MTCs, no dedicated cohorts have been studied with SPET-CT, although some utility is reported [98, 99] .
SPET-CT for miscellaneous uses related to thyroid cancer SPET imaging with CT has also been fused with MRI for the investigation of thyroid cancer metastases [50] . It has been used to guide aspiration biopsy, when the ultrasound fine-needle aspiration biopsy is negative, but the lymph node aspirate is positive for thyroglobulin [100, 101] . A novel use is to predict nodal metastatic status with 99m Tcsestamibi [102] . Future use of these novel applications of SPET-CT remains to be elucidated.
Conclusion
SPET-CT imaging has improved our ability to localize disease and distinguish benign and otherwise normal Clin Transl Imaging (2014) 2:459-475 471
anatomical variants from thyroid cancer in the neck and elsewhere. The addition of anatomical maps that can be directly combined with the distribution of radioiodine in multi-planar orthogonal projections has changed the approach to diagnosis, staging, therapy and prognostic assessment of well-differentiated thyroid cancer.
